ckd-519
Small moleculeexperimental
Clinical trial activity
9 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2014 (NCT02156544)
Timeline
Indications
Mechanism of action
- Cholesteryl ester transfer proteinINHIBITOR
CETP inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ckd-519
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03175835 | Phase 1 | May 8, 2017 | Chong Kun Dang Pharmaceutical |
| NCT03210649 | Phase 1 | Mar 7, 2017 | Chong Kun Dang Pharmaceutical |
| NCT02977065 | Phase 2 | Jan 1, 2017 | Chong Kun Dang Pharmaceutical |
| NCT02894541 | Phase 1 | Aug 1, 2016 | Chong Kun Dang Pharmaceutical, Korea University |
| NCT02916901 | Phase 1 | Aug 1, 2016 | Chong Kun Dang Pharmaceutical, Yonsei University |
| NCT02753504 | Phase 1 | Apr 1, 2016 | Chong Kun Dang Pharmaceutical, Yonsei University |
| NCT02623868 | Phase 1 | Oct 1, 2015 | Chong Kun Dang Pharmaceutical, Korea University |
| NCT02484482 | Phase 1 | Jun 1, 2015 | Chong Kun Dang Pharmaceutical |
| NCT02156544 | Phase 1 | Jun 1, 2014 | Chong Kun Dang Pharmaceutical, Yonsei University |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chong Kun Dang Pharmaceutical | For profit | 9 | 9 | 2 | 2014 |
| Yonsei University | Academic/Hospital | 3 | 0 | 1 | 2014 |
| Korea University | Academic/Hospital | 2 | 0 | 1 | 2015 |
3 organizations
Page 1 / 1